EXJADE (deferasirox)
TherapyNovartis
EXJADE (deferasirox) by Novartis is an oral iron chelator used in transfusion-related iron overload settings.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and EXJADE. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where EXJADE is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Non-Transfusion-Dependent Thalassemia Non-cancer · Blood | Liver iron concentration imaging
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for EXJADE.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering EXJADE for eligible patients.
Test
FerriScan
Resonance Health Analysis Services Pty Ltd
Method
IMAGING
1 approvalView test profile →